Comparative study of torque expression and its biomechanical effects: spherical self-ligating bracket with lock-hook system versus passive self-ligating bracket and conventional bracket.

Background: Proper torque control is crucial to the outcome of orthodontic treatment. This study aimed to employ finite element analysis to compare the torque capabilities of a novel spherical self-ligating bracket with a lock-hook system against those of commonly used passive self-ligating and conventional bracket systems, as well as to reveal the biomechanical changes in the periodontal ligament (PDL) during torque expression.

Methods: A maxillary right central incisor, along with its PDL and alveolar bone, were modeled.

Retraction Notice to: MYB Proto-oncogene-like 1-TWIST1 Axis Promotes Growth and Metastasis of Hepatocellular Carcinoma Cells.

[This retracts the article DOI: 10.1016/j.omto.

Selective Adsorption of Chlorine Species on RuO Sites for Efficient Elimination of Vinyl Chloride on the Ru/SnO Catalyst.

The main bottleneck in the catalytic combustion of chlorinated volatile organic compounds (CVOCs) is deactivation and the production of chlorine-containing byproducts originating from the chlorine species deposited on the catalyst. Herein, Ru supported on SnO (Ru/SnO) was prepared with the lattice matching principle. As RuO and SnO are both rutile phases, Ru species were present as highly dispersed RuO particles on the Ru/SnO catalyst.

Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.

Objective: The objective of this study is to evaluate the efficacy and safety of jaktinib hydrochloride tablets (jaktinib), a Janus kinase inhibitor, in patients with active radiographic axial spondyloarthritis (r-axSpA).

Methods: Adults with active r-axSpA who met modified New York criteria and had an inadequate response to non-steroidal anti-inflammatory drugs were randomised 1:1:1 to receive jaktinib 75 mg two times per day, 100 mg two times per day, or placebo. The primary and key secondary endpoints were Assessment of SpondyloArthritis international Society 20 (ASAS 20) and ASAS 40 responses, respectively, at week 16.

Mifepristone achieves tumor suppression and ferroptosis through PR/p53/HO1/GPX4 axis in meningioma cells.

Purpose: This study explores the effects of mifepristone on the proliferation, motility, and invasion of malignant and benign meningioma cells, aiming to identify mifepristone-sensitive types and investigate the underlying molecular mechanisms.

Methods: IOMM-Lee and HBL-52 meningioma cells were treated with 0, vehicle control (VC), 5, 10, 20, 40, and 80 μM of mifepristone for 12, 24, 48, 72, and 96 h. Proliferation was assessed via CCK8 assay, while motility and invasion were measured using wound scratch and transwell assays.